Vigamox is a drug owned by Harrow Eye Llc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2020. Details of Vigamox's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7671070 (Pediatric) | Method of treating ophthalmic infections with moxifloxacin compositions |
Mar, 2020
(4 years ago) |
Expired
|
|
US6716830 (Pediatric) | Ophthalmic antibiotic compositions containing moxifloxacin |
Mar, 2020
(4 years ago) |
Expired
|
| US6716830 | Ophthalmic antibiotic compositions containing moxifloxacin |
Sep, 2019
(5 years ago) |
Expired
|
| US7671070 | Method of treating ophthalmic infections with moxifloxacin compositions |
Sep, 2019
(5 years ago) |
Expired
|
|
US5607942 (Pediatric) | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Sep, 2014
(10 years ago) |
Expired
|
| US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Vigamox and ongoing litigations to help you estimate the early arrival of Vigamox generic.
Vigamox's Litigations
Vigamox been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 12, 2012, against patent number US7671070. The petitioner Apotex Inc., challenged the validity of this patent, with Alcon as the respondent. Click below to track the latest information on how companies are challenging Vigamox's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6716830 | October, 2012 |
Terminated-Settled
(15 Nov, 2013) | Alcon Pharmaceuticals Ltd. | Apotex Inc. |
| US7671070 | October, 2012 |
Terminated-Settled
(15 Nov, 2013) | Alcon | Apotex Inc. |
US patents provide insights into the exclusivity only within the United States, but Vigamox is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vigamox's family patents as well as insights into ongoing legal events on those patents.
Vigamox's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vigamox's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 29, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vigamox Generic API suppliers:
Moxifloxacin Hydrochloride is the generic name for the brand Vigamox. 20 different companies have already filed for the generic of Vigamox, with Lupin Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vigamox's generic
How can I launch a generic of Vigamox before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Vigamox's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Vigamox's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Vigamox -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.005 | 22 Dec, 2005 | 1 | 20 Sep, 2019 | Extinguished |
Alternative Brands for Vigamox
Vigamox which is used for treating bacterial infections in patients., has several other brand drugs in the same treatment category and using the same active ingredient (Moxifloxacin Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Moxifloxacin Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Bayer Hlthcare |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Moxifloxacin Hydrochloride, Vigamox's active ingredient. Check the complete list of approved generic manufacturers for Vigamox
About Vigamox
Vigamox is a drug owned by Harrow Eye Llc. It is used for treating bacterial infections in patients. Vigamox uses Moxifloxacin Hydrochloride as an active ingredient. Vigamox was launched by Harrow Eye in 2003.
Approval Date:
Vigamox was approved by FDA for market use on 15 April, 2003.
Active Ingredient:
Vigamox uses Moxifloxacin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Moxifloxacin Hydrochloride ingredient
Treatment:
Vigamox is used for treating bacterial infections in patients.
Dosage:
Vigamox is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.5% BASE | SOLUTION/DROPS | Prescription | OPHTHALMIC |